Probable Levofloxacin-Induced Thrombocytopenia in a Patient Previously on Ciprofloxacin: A Case Report and Literature Review

Drug-induced thrombocytopenia is a poorly understood, yet common phenomenon widely encountered in clinical practice. We present a case of suspected levofloxacin-induced thrombocytopenia, a rare side effect of a ubiquitous antibiotic, in a patient without similar effect to ciprofloxacin. This report builds upon other isolated case reports of fluoroquinolone-induced thrombocytopenia and demonstrates our algorithmic approach to the issue as well as a literature review pertaining to fluoroquinolone-induced thrombocytopenia.

Download Full-text

Bevacizumab-induced dysphonia: A case report with brief review of literature

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155219889388 ◽

2019 ◽

Vol 26 (4) ◽

pp. 1032-1036

Author(s):

So Yi Lam ◽

Chung-Shien Lee ◽

Sandhya Sharma ◽

Kit Cheng

Keyword(s):

Ovarian Cancer ◽

Case Report ◽

Side Effect ◽

Case Reports ◽

Palliative Therapy ◽

Ovarian Adenocarcinoma ◽

Voice Changes ◽

Patient Reported ◽

Rare Side Effect

Introduction Anti-angiogenic treatment in adjunct with chemotherapy is widely used for the treatment of various cancers. These agents inhibit vascular endothelial growth factor (VEGF) signaling thereby inhibiting tumor proliferation and invasion. Dysphonia, or voice changes, has been documented, but is an underreported side effect of anti-angiogenic agents. We report a case of intermittent dysphonia in a patient with metastatic, platinum-refractory ovarian cancer treated with bevacizumab. Case report A 48-year-old female with high grade mixed type ovarian adenocarcinoma and concurrent left sided breast cancer was transitioned to palliative therapy with gemcitabine-bevacizumab for her ovarian cancer. At a follow-up visit after three cycles of the new therapy, the patient complained of intermittent changes in her voice, describing periods of hoarseness or softness in her voice after the chemotherapy—sometimes to the point that her voice was inaudible. Management and outcome: A new pelvic thrombus was discovered upon assessment of the patient’s disease. Bevacizumab was held and she was referred to ear, nose, and throat evaluation for dysphonia. Laryngoscopic examination showed normal vocal cord, with normal movements and no lesion or necrosis. During subsequent follow-up, the patient reported improvement in her voice with no additional dysphonia. Discussion Vocal adverse effects of anti-VEGF agents have been documented in landmark trials and case reports; however, clinicians are often unaware of this rare side effect. Although VEGF-induced dysphonia may be rare and may not impede the patient’s quality of life in some cases, it is critical to acknowledge and not underestimate this adverse effect.

Download Full-text

Ejaculatory Dysfunction Produced by Clozapine. Three Case Reports and Review of Pathophysiological Mechanisms

Urologia Journal ◽

10.1177/039156039306000413 ◽

1993 ◽

Vol 60 (4) ◽

pp. 354-356

Author(s):

Y. Talmon ◽

M. Guy ◽

S. Eisenkraft ◽

N. Guy

Keyword(s):

Drug Therapy ◽

Side Effect ◽

Case Reports ◽

Retrograde Ejaculation ◽

Anti Psychotic ◽

Drug Induced ◽

Pathophysiological Mechanisms ◽

Rare Side Effect ◽

Schizophrenic Patients ◽

Ejaculatory Dysfunction

Three chronic paranoid schizophrenic patients were treated with clozapine, a new anti-psychotic agent. Retrograde ejaculation developed as a side-effect. Stopping the drug therapy or reducing the dosage caused the side-effect to disappear. Re-challenge caused the return of the side-effect. We discuss this rare side-effect to clozapine, and the pathophysiological mechanisms of ejaculation disturbances, with emphasis on those that are drug-induced.

Download Full-text

RIFAXIMIN INDUCED HYPONATREMIA: A CASE REPORT

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2016.v9s3.14452 ◽

2016 ◽

Vol 9 (9) ◽

pp. 1 ◽

Cited By ~ 1

Author(s):

Shalini Upadhyay ◽

Prabhat Agrawal ◽

Manish Bansal ◽

Anjalika Gupta

Keyword(s):

Irritable Bowel Syndrome ◽

Case Report ◽

Clinical Practice ◽

Side Effects ◽

Side Effect ◽

Aged Woman ◽

Rare Side Effect ◽

Middle Aged Woman ◽

The Common ◽

Irritable Bowel

ABSTRACTRifaximin is one of the common drugs used in clinical practice in the management of traveler’s diarrhea, irritable bowel syndrome (IBS), and hepaticencephalopathy. Hyponatremia is one of the rare side effects of this drug. We hereby present the case of a middle-aged woman who was a known caseof IBS: Diarrhea predominant who developed symptoms of hyponatremia after a short duration of rifaximin treatment, no other cause of hyponatremiawas found on evaluation, so we suspect this as a rare side effect of rifaximin therapy.Keywords: Rifaximin, Hyponatremia, Irritable bowel syndrome.

Download Full-text

Sodium Polystyrene Sulfonate-Induced Gastric Pneumatosis: A Rare Side Effect

Case Reports in Gastroenterology ◽

10.1159/000518929 ◽

2021 ◽

pp. 878-883

Author(s):

Neethi Dasu ◽

Yaser Khalid ◽

Kirti Dasu ◽

Lucy Joo ◽

Brian Blair

Keyword(s):

Case Report ◽

Side Effects ◽

Side Effect ◽

Case Reports ◽

Sodium Polystyrene Sulfonate ◽

Polystyrene Sulfonate ◽

Unique Case ◽

Rare Side Effect ◽

Colonic Necrosis ◽

The Usa

Kayexalate has been used in the USA since 1975 for the treatment of hyperkalemia. Prior case reports have shown that sorbitol added to kayexalate has been known to cause rare side effects of colonic necrosis. We present a unique case report of gastric pneumatosis as a complication of kayexalate.

Download Full-text

Oseltamivir-induced behavioral changes in a female Lebanese adolescent: a case report of a usual drug with unusual side effect

Future Science OA ◽

10.2144/fsoa-2019-0162 ◽

2020 ◽

pp. FSO602 ◽

Cited By ~ 1

Author(s):

Rabih Fares ◽

Antoine Zgheib ◽

Rabih Hallit ◽

Souheil Hallit

Keyword(s):

Abdominal Pain ◽

Case Report ◽

Literature Review ◽

Side Effect ◽

Case Reports ◽

Neuropsychiatric Symptoms ◽

Female Adolescent ◽

Behavioral Changes ◽

Abnormal Behavior ◽

Behavioral Activities

Neuropsychiatric symptoms, including abnormal behavior, after oseltamivir use among influenza patients have been of concern. In recent years, many case reports of neuropsychiatric events during or after oseltamivir treatment were reported; however, literature review revealed no such cases in Lebanon. Oseltamivir is the most widely prescribed medication against influenza and is generally well tolerated, causing random gastrointestinal disturbances, including nausea, vomiting, diarrhea and abdominal pain. However, in rare instances, it has been reported to stimulate behavioral activities in adolescents. We report herein a case of an oseltamivir-related neuropsychiatric event in a female adolescent in Lebanon, which resolved 2 days after stopping the drug.

Download Full-text

May psychosis be a rare side-effect of sildenafil? A case-report

10.26226/morressier.5d1a037757558b317a1406ef ◽

2019 ◽

Author(s):

Mohammadreza Shalbafan ◽

Leila Kamalzadeh

Keyword(s):

Case Report ◽

Side Effect ◽

Rare Side Effect

Download Full-text

Reticular erythematous mucinosis: Literature review and case report of a 24-year-old patient with systemic erythematosus lupus

Lupus ◽

10.1177/0961203320965702 ◽

2020 ◽

pp. 096120332096570

Author(s):

Juliana P Ocanha-Xavier ◽

Camila O Cola-Senra ◽

Jose Candido C Xavier-Junior

Keyword(s):

Systematic Review ◽

Case Report ◽

Literature Review ◽

English Language ◽

Case Reports ◽

Histopathological Diagnosis ◽

Skin Disorders ◽

Histopathological Findings ◽

Inflammatory Skin

Reticular erythematous mucinosis (REM) was first described 50 years ago, but only around 100 case reports in English have been published. Its relation with other inflammatory skin disorders is still being debated. We report a case of REM, including the clinical and histopathological findings. Also, a systematic review of 94 English-language reported cases is provided. The described criteria for clinical and histopathological diagnosis are highlighted in order to REM can be confidently diagnosed.

Download Full-text

Clozapine-induced stuttering in the absence of known risk factors: a case report

Journal of Medical Case Reports ◽

10.1186/s13256-021-02803-8 ◽

2021 ◽

Vol 15 (1) ◽

Author(s):

Florence Jaguga

Keyword(s):

Risk Factors ◽

Family History ◽

Side Effect ◽

Case Reports ◽

Extrapyramidal Symptoms ◽

Prior History ◽

Case Presentation ◽

Rare Side Effect ◽

History Of ◽

Electrophysiological Findings

Abstract Background Stuttering is a rare side effect of clozapine. It has been shown to occur in the presence of one or more factors such as abnormal electrophysiological findings and seizures, extrapyramidal symptoms, brain pathology, and a family history of stuttering. Few case reports have documented the occurrence of clozapine-induced stuttering in the absence of these risk factors. Case presentation A 29-year-old African male on clozapine for treatment-resistant schizophrenia presented with stuttering at a dosage of 400 mg/day that resolved with dose reduction. Electroencephalogram findings were normal, and there was no clinical evidence of seizures. The patient had no prior history or family history of stuttering, had a normal neurological examination, and showed no signs of extrapyramidal symptoms. Conclusion Clinicians ought to be aware of stuttering as a side effect of clozapine, even in the absence of known risk factors. Further research should investigate the pathophysiology of clozapine-induced stuttering.

Download Full-text